¾È³çÇϼ¼¿ä 7/15 ¹ßÇ¥ÀÚ ¿äÇÑÀÔ´Ï´Ù.
Á¦°¡ ¹ßÇ¥ÇÒ ³í¹®Àº 2022³â Annals of the Rheumatic Diseases¿¡ ÃâÆǵÈ
‘
TFH cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal center formation and autoimmunity’ÀÔ´Ï´Ù.
IL-1β´Â normal immunization°ú autoimmunityÀÇ antibody response¿¡ ±â¿©ÇÑ´Ù°í ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ IL-1β´Â NLRP3 inflammasome¿¡ ÀÇÇÑ caspase-1ÀÇ È°¼ºÀ¸·ÎºÎÅÍ Çü¼ºµÈ´Ù°íµµ Àß ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.
¶ÇÇÑ IL-1β°¡ CD4+ T cell¿¡¼ antigen driven expansion°ú differentiationÀ» °ÈÇÑ´Ù°íµµ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù¸¸, CD4+ T cell¿¡¼ »ý¼ºµÇ´Â IL-1βÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ¿¬±¸°¡ ºÎÁ·ÇÑ ½ÇÁ¤ÀÔ´Ï´Ù.
ÀÌ¿¡ º» ¿¬±¸ÆÀÀº NLRP3 activationÀÌ TFH cellÀÇ T dependentÇÑ antigen¿¡ ´ëÇÑ humoral response¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù´Â °ÍÀ» ¹àÇû½À´Ï´Ù.
±× ¹æ¹ýÀ¸·Î´Â NLRP3¿¡ specificÇÑ inhibitorÀÎ MCC950À» »ç¿ëÇÏ¿© immunizationµÈ mouseÀÇ Germinal center, spleen ¹× antibody secretion °ú affinity maturation µîÀ» ÆľÇÇÏ¿´À¸¸ç,
B6.NLRP3fl/flCreLCK ¸¶¿ì½º ¸ðµ¨À» »ç¿ëÇÏ¿© IgM, IgGÀÇ affinity maturation°ú antibody response µîÀ» È®ÀÎÇÏ¿´½À´Ï´Ù.
¸¶Áö¸·À¸·Î ÀÌ·¯ÇÑ NLRP3 inflammasomeÀÌ autoimmunity¿¡¼´Â ¾î¶°ÇÑ ¿ªÇÒÀ» È®ÀÎÇϱâ À§ÇØ SLE mouse modelÀÎ MRL/lpr ¸¶¿ì½º¿¡¼ NLRP3ÀÇ È°¼ºÀ» È®ÀÎÇÏ°í, MCC950À» ó¸®ÇÏ¿© Áúº´ÀÇ parameter µîÀÇ ¿Ïȸ¦ °üÂûÇÏ¿´½À´Ï´Ù.
¶ÇÇÑ SLE patientÀÇ PBMC¸¦ ÅëÇØ SLE patientµéÀÇ TFH¿¡¼ ³ôÀº NLRP3 inflammasome activationÀ» È®ÀÎÇÏ¿´À¸¸ç, Ãß°¡ÀûÀ¸·Î hydroxychloroquine µîÀÇ immunosuppressive ¾à¹°À» Åõ¿©ÇÑ È¯ÀÚ¿¡¼ ÀÌ·¯ÇÑ NLRP3 inflammasome activationÀÌ °¨¼ÒÇÏ´Â °Í ¶ÇÇÑ ¹ß°ßÇÏ¿´½À´Ï´Ù.
À§ ³í¹®À» °øºÎÇÑ ÀÌÀ¯´Â, ÃÖ±Ù NLRP3 inflammasome¿¡ ´ëÇؼ °øºÎÇϸç, ÀÌ·¯ÇÑ inflammasomeÀÌ macrophage, monocytes, DC»Ó¸¸ ¾Æ´Ï¶ó CD4+ T cell¿¡¼µµ Çü¼ºµÇ¸ç humoral immune response¿¡ °ü¿©ÇÑ´Ù´Â °ÍÀ» ¾Ë°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ °ü½É ÀÖ´Â ÁÖÁ¦ Áß ÇϳªÀÎ autoimmune condition¿¡¼ ÀÌ·¯ÇÑ CD4+ T cellÀÇ NLRP3 inflammasomeÀÌ ¾î¶°ÇÑ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö °øºÎÇϱâ À§Çؼ ¼±Á¤ÇÏ°Ô µÇ¾ú½À´Ï´Ù.
¿½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
±è¿äÇÑ ¿Ã¸²
³í¹® ¸µÅ©:
¹Ù·Î °¡±â